X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Biogen will have access to pipeline a range of immune-mediated diseases, including MOR202 (felzartamab), being evaluated for treating primary membranous nephropathy.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: HI-Bio
Deal Size: $1,800.0 million Upfront Cash: $1,150.0 million
Deal Type: Acquisition July 02, 2024
Details:
Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
EC has granted approval for TOFIDENCE, a biosimilar monoclonal antibody referencing ROACTEMRA, for moderate to severe active rheumatoid arthritis, systemic juvenile idiopathic arthritis, etc.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: Tofidence
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
Qalsody (tofersen), an ASO designed to bind to SOD1 mRNA to reduce SOD1 protein production. FDA granted accelerated approval for amyotrophic lateral sclerosis having SOD1 gene mutation.
Lead Product(s): Tofersen
Therapeutic Area: Neurology Product Name: Qalsody
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
Through the acquisition, Biogen will have access to pipeline-in-a-product across a range of immune-mediated diseases, including MOR202 (felzartamab), a potential first-in-class therapeutic candidate being evaluated for treating primary membranous nephropathy.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: HI-Bio
Deal Size: $1,800.0 million Upfront Cash: $1,150.0 million
Deal Type: Acquisition May 22, 2024
Details:
BIIB105 (ION541) is an investigational oligonucleotide designed to reduce the production of the ataxin-2 (ATXN2) protein. It is being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): ION541
Therapeutic Area: Neurology Product Name: BIIB105
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Ionis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
Details:
Tofidence (tocilizumab-biosimilar) is a recombinant IL-6 receptor inhibitor, monoclonal antibody. It is being evaluated for moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis & COVID-19.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: Tofidence
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
The collaboration aims to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2024
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Product Name: Spinraza
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Qalsody (tofersen) is an antisense oligonucleotide designed to bind to SOD1 mRNA to reduce SOD1 protein production. The U.S. FDA granted accelerated approval for QALSODY to treat amyotrophic lateral sclerosis in adults who have a mutation in the SOD1 gene.
Lead Product(s): Tofersen
Therapeutic Area: Neurology Product Name: Qalsody
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
